Drug Type Proteolysis-targeting chimeras (PROTAC) |
Synonyms |
Target |
Mechanism BTK inhibitors(Tyrosine-protein kinase BTK inhibitors) |
Therapeutic Areas |
Active Indication |
Inactive Indication- |
Originator Organization- |
Active Organization |
Inactive Organization- |
Drug Highest PhasePreclinical |
First Approval Date- |
Regulation- |
Molecular FormulaC52H59N11O3 |
InChIKeyXINQZYKFOMWJAY-UHFFFAOYSA-N |
CAS Registry- |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Diffuse Large B-Cell Lymphoma | Preclinical | CN | 29 Sep 2022 | |
Diffuse Large B-Cell Lymphoma | Preclinical | CN | 29 Sep 2022 | |
Diffuse Large B-Cell Lymphoma | Preclinical | CN | 29 Sep 2022 | |
Diffuse Large B-Cell Lymphoma | Preclinical | CN | 29 Sep 2022 |